Free Trial

Syros Pharmaceuticals Q4 2023 Earnings Report

Syros Pharmaceuticals logo
$0.03 0.00 (-10.86%)
As of 03/28/2025 03:59 PM Eastern

Syros Pharmaceuticals EPS Results

Actual EPS
-$1.19
Consensus EPS
-$1.23
Beat/Miss
Beat by +$0.04
One Year Ago EPS
N/A

Syros Pharmaceuticals Revenue Results

Actual Revenue
$0.39 million
Expected Revenue
$2.40 million
Beat/Miss
Missed by -$2.01 million
YoY Revenue Growth
N/A

Syros Pharmaceuticals Announcement Details

Quarter
Q4 2023
Time
N/A

Conference Call Resources

Remove Ads

Syros Pharmaceuticals Earnings Headlines

Trump to unlock 15-figure fortune for America (May 3rd) ?
We were shown this map by former Presidential Advisor, Jim Rickards, one of the most politically connected men in America. Rickards has spent his fifty-year career in the innermost circles of the U.S. government and banking. And he believes Trump could soon release this frozen asset to the public.
See More Syros Pharmaceuticals Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Syros Pharmaceuticals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Syros Pharmaceuticals and other key companies, straight to your email.

About Syros Pharmaceuticals

Syros Pharmaceuticals (NASDAQ:SYRS), a biopharmaceutical company, focuses on the development of treatment for hematologic malignancies. The company's lead product candidates are Tamibarotene, a selective retinoic acid receptor alpha agonist, which is in Phase III clinical trial for genomically defined subset of patients with myelodysplastic syndrome and Phase II clinical trial for patients with acute myeloid leukemia; SY-2101, a novel oral form of arsenic trioxide for treating patients with acute promyelocytic leukemia; and SY-5609, a cyclin-dependent kinase 7 inhibitor, which is in a Phase I clinical trial in patients with select advanced solid tumors. The company was formerly known as LS22, Inc. and changed its name to Syros Pharmaceuticals, Inc. in August 2012. Syros Pharmaceuticals, Inc. was incorporated in 2011 and is headquartered in Cambridge, Massachusetts.

View Syros Pharmaceuticals Profile

More Earnings Resources from MarketBeat